How to prevent herpes outbreak during period

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Elizabeth Micks, MD, MPH, Hyunju Son, MS, Amalia Magaret, PhD, Stacy Selke, MA, Christine Johnston, MD, MPH, and Anna Wald, MD, MPH

Elizabeth Micks

Department of Obstetrics and Gynecology University of Washington 1959 NE Pacific St. Box 356460, Seattle, WA 98122, USA

Find articles by Elizabeth Micks

Hyunju Son

Department of Biostatistics University of Washington Seattle, WA 98122, USA

Find articles by Hyunju Son

Amalia Magaret

Departments of Laboratory Medicine and Biostatistics University of Washington Seattle, WA 98122, USA

Find articles by Amalia Magaret

Stacy Selke

Department of Laboratory Medicine University of Washington Seattle, WA 98122, USA

Find articles by Stacy Selke

Christine Johnston

Department of Medicine University of Washington Seattle, WA 98122, USA

Find articles by Christine Johnston

Anna Wald

Departments of Medicine, Laboratory Medicine, and Epidemiology University of Washington Seattle, WA 98122, USA

Find articles by Anna Wald

Author information Copyright and License information Disclaimer

Elizabeth Micks, Department of Obstetrics and Gynecology University of Washington 1959 NE Pacific St. Box 356460, Seattle, WA 98122, USA;

Contributor Information.

Corresponding author Elizabeth Micks MD, MPH, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St. Box 356460, Seattle, WA 98122, USA, Fax: 206-543-3915, Phone: 206-616-4939, ude.wu@skcime

Copyright notice

The publisher's final edited version of this article is available at Sex Transm Dis

Brief Summary:

Among HSV-2 seropositive women, the follicular phase of the cycle was associated with a higher frequency of genital HSV-2 shedding. Hormonal contraception did not affect HSV-2 shedding or lesions.

Background:

The effect of female sex hormones on HSV-2 shedding and lesion frequency is poorly understood. Previous studies suggest that hormonal contraception may increase the frequency of HSV-2 shedding.

Methods:

We studied HSV-2 seropositive women who performed daily genital swabbing for HSV DNA and completed diaries for genital lesions and menses. We used Poisson mixed effects models to determine if HSV detection varied throughout the menstrual cycle, or in response to hormonal contraception. We used the Wilcoxon signed-rank test and rank-sum test to determine if lesion frequency differed by cycle phase or hormonal contraceptive use.

Results:

In 189 women aged 19–46 who collected swabs on 10,715 days and were not using hormonal contraception, HSV-2 DNA was detected on 20.9% of days in the follicular phase and 17.8% of days in the luteal phase (RR=1.19; 95% CI 1.03–1.37, p=0.02). Genital lesions did not differ in the follicular versus luteal phase (12.8% versus 10.7%, p=0.07). In analyses of hormonal contraception, including 244 women, HSV-2 DNA was detected on 19.0% of days for women not using hormonal contraception and 18.3% of days for those using hormonal contraception (p=0.50). Lesions were present on 11.1% of days for women not using hormonal contraception, and 8.7% of days for those using hormonal contraception (p=0.66).

Conclusion:

In women with genital HSV-2 infection who are not using hormonal contraception, the follicular phase of the cycle may be associated with a higher frequency of HSV-2 shedding compared to the luteal phase. Lesion frequency is similar during the two menstrual phases. Hormonal contraception use was not observed to affect genital HSV-2 DNA detection or lesions.

Keywords: HSV, shedding, genital herpes, contraception, menstrual cycle, luteal, follicular, progesterone

Introduction

Genital herpes simplex virus-2 (HSV-2) is the leading cause of genital ulcer disease worldwide.1 HSV-2 increases the risk of human immunodeficiency virus (HIV) acquisition two to three-fold, and nearly half of new HIV infections are attributable to previous infection with HSV-2 in high prevalence settings.2 Genital ulcers also increase the risk of HIV transmission.3 Neonatal herpes, which can be fatal or associated with permanent impairment, is another serious clinical consequence of HSV-2 which is estimated to affect 14,000 infants per year worldwide.4

The vast majority of new HSV-2 infections are transmitted from partners who have no history of genital ulcers.5 Even among persons with a known history of genital herpes, most transmissions occur in the absence of lesions.6 Few determinants of shedding rates have been described and the unpredictability of viral shedding is frustrating to patients.7 Though symptomatic infections are associated with a greater frequency of shedding, asymptomatic persons have been found to shed HSV-2 in the genital tract on approximately 10% of days.8 There is substantial individual variation in shedding frequency and quantity.9 A greater quantity of HSV-2 is detected in the presence of lesions compared to days without lesions. However, when no lesions are present, persons with symptomatic and asymptomatic HSV-2 infections appear to shed similar quantities of virus.8

The effect of female sex hormones on HSV-2 shedding and lesions is poorly understood. Previous studies suggest that vaginal immunity varies throughout the menstrual cycle in response to changes in endogenous sex hormones.10–12 The luteal phase of the cycle, which occurs after ovulation and is characterized by a specific hormonal profile including elevated serum progesterone and estradiol, is associated with increased inflammatory cytokines and decreased innate immune factors.10,13,14 Increased susceptibility to sexually transmitted infections has also been noted during this phase in animal models.12 Whether the frequency of HSV shedding or lesion occurrence vary throughout the menstrual cycle is not known. However some women anecdotally report more genital herpes outbreaks during menses and one study of the natural history of untreated genital herpes suggested such an association.15 Given the delay between known immune triggers (mucosal trauma or fever, for instance) and HSV-2 reactivation in neurons with latent infection, it is possible that a reduction in immunity during the luteal phase would lead to an increased risk of viral reactivation and the development of shedding or lesions during the subsequent weeks.

We aimed to determine whether there is an association between menstrual cycle phase, hormonal contraceptive use, and HSV-2 shedding or lesions in a large cohort of women. We hypothesized that HSV-2 shedding and lesions would be more frequent in the follicular phase of the cycle among women not using hormonal contraception and more frequent among hormonal contraceptive users.

Materials and Methods

Participants

HSV-2 seropositive women between ages 18 and 46 were enrolled into prospective studies at the University of Washington Virology Research Clinic (Seattle, Washington) between February 1991 and September 2016. Women with and without a history of genital lesions were eligible for this analysis if they were seropositive for HSV-2, recorded menstrual dates using a daily diary and provided information regarding use of hormonal contraception. Women within a year of primary HSV-2 infection (laboratory documented or based on self-report) were excluded in order to remove potential confounding by time since acquisition. Individuals who were using antiviral medication at the time of the swabbing session were excluded from the analysis. This study was approved by the Institutional Review Board at the University of Washington.

Sample and Data Collection

Participants were instructed in the once-daily collection of mixed anogenital swabs as previously reported.8,16 Briefly, participants inserted a single Dacron swab into the vagina for one minute. The swab was then used to sample genital secretions from bilateral labia majora and minora, perineum, and perianal region, then placed into a 1mL tube containing 1X PCR buffer. Women completed the same swabbing sequence in the presence and absence of menses. Participants completed a daily diary noting genital symptoms and lesions, sexual activity, and menstrual bleeding. Hormonal contraceptive use was determined based on participant self-report at the time of swabbing session initiation, typically indicated by a yes or no question; specific type of hormonal contraception was not recorded. For women with multiple swabbing sessions (distinct periods of time in which they collected daily swabs), we included only the first two sessions. Only the first session was included if contraceptive status changed over time.

Laboratory Studies

HSV serostatus was determined by the University of Washington HSV Western Blot.17 To assess the presence of HSV-2 genital shedding, HSV DNA on genital swabs was detected with real-time fluorescence-based quantitative polymerase chain reaction (PCR) using primers to glycoprotein B, as previously described.18

Statistical Analysis

HSV shedding frequency was defined as the number of days with genital swabs with HSV detected divided by the total number of days with genital swabs collected. Similarly, lesion frequency was defined as the number of days with reported genital lesions divided by the total number of days with diary data.

The menstrual cycle analysis included only women who indicated they were not using hormonal contraception. HSV shedding and lesion data were included if they were within 14 days of recorded first day of menstrual bleeding. The menstrual cycle was divided into phases based on most proximate first day of menstrual bleeding. Follicular phase was defined as days 0 to 13 after the first day of bleeding, and luteal phase was defined as days 1 to 14 prior to bleeding. We further subdivided the follicular and luteal phases into four seven-day phases (early follicular: 0 to 6 days after first day of menses; late follicular: 7 to 13 days after first day of menses; early luteal: 8 to 14 days prior to first day of menses; late luteal: 1 to 7 days prior to first day of menses). Frequencies of HSV shedding were calculated by menstrual phase, and we assessed differences in shedding frequencies by menstrual phase using a Poisson mixed model, including a random intercept for individual to account for the correlation in repeated measures within individuals. In the analysis of genital lesions, we relied on a nonparametric approach due to sparse data. We used the Wilcoxon signed-rank test for paired data to compare lesion frequencies at different phases of the menstrual cycle. Due to concerns about misclassification of menstrual phase for days further from first day of menses, a sensitivity analysis was conducted using only measures taken within 10 days of the start of menses.

The HSV shedding frequency was compared in women using versus not using hormonal contraception with a Poisson mixed model. Lesion frequencies were compared between groups using the Wilcoxon rank-sum test. Assuming that most women on hormonal contraception in this population use cyclic oral contraceptives and initiate a hormone-free interval (placebo pills) just prior to menses, we used similar analyses to determine whether HSV shedding or lesion frequencies were associated with menses (cycle days 0 to 6) in hormonal contraceptive users.

For both the menstrual cycle analysis and the hormonal contraception analysis, the mean duration of HSV-2 shedding episodes and the quantity of HSV-2 DNA were compared using linear mixed effects models. A two-sided P value less than 0.05 was considered to be statistically significant.

Results

We identified 244 eligible women who collected 12,059 daily genital swabs and recorded a lesion diary on 13,237 days. The median age was 32 years (range 19 to 46). The median time since HSV-2 infection was 6 years (range 1 to 28 years), and women had a median of 4 genital herpes recurrences per year (range 0 to 28).

Menstrual cycle phase:

Among the 189 women who reported not using hormonal contraception, HSV DNA was detected on 1,030 of 4936 days (20.9%) in the follicular phase of the cycle compared to 726 of 4073 days (17.8%) in the luteal phase of the cycle (RR=1.19; 95% CI 1.03–1.37, p=0.02). Figure 1a demonstrates shedding rates among participants when menstrual cycle was further divided into early and late follicular, and early and late luteal. Though shedding frequency appeared higher in the early and late follicular phases, none of the individual comparisons were statistically significant.

Open in a separate window

Figure 1.

Bar plots of overall HSV-2 shedding frequency (a) and lesion frequency (b) at different phases of the menstrual cycle.

Genital lesions were reported on 687 of 5372 days (12.8%) in the follicular phase, versus 478 of 4480 days (10.7%) in the luteal phase, though this difference was not statistically significant (p=0.07) (Figure 1b). Median duration of shedding episodes was 3 days for the follicular phase (range 1 to 32 days) versus 2 days for the luteal phase (range 1 to 17 days), and this difference was not statistically significant (p=0.61). On days HSV-2 DNA was detected, the quantity of virus shed was the same (4.7 log10 copies/mL in the follicular and luteal phase; p=0.61).

These findings were reproduced in the planned sensitivity analysis limited to data within 10 days before or after the first day of menses. HSV detection was higher in the follicular phase (21.4%) versus the luteal phase (17.3%) (RR 1.25, 95% CI 1.06–1.48, p=0.01). Lesion frequency was also higher in the follicular phase (13.1% versus 10.2%, p=0.05).

Hormonal contraception

Sixty-eight (28%) of the 244 participants reported using hormonal contraception during the study period (Table 1). Women who did and did not use hormonal contraception were similar in age, number of genital herpes recurrences per year, and time since HSV-2 infection. HSV-2 DNA was detected on 675 of 3691 daily swabs (18.3%) for those using hormonal contraception and 2036 of 10715 swabs (19%) for women not using hormonal contraception (RR=1.16; 95% CI 0.75–1.79, p=0.50) (Table 2). Genital lesions were present on 320 of 3677 days (8.7%) for those using hormonal contraception and 1272 of 11447 days (11.1%) for women not using hormonal contraception (p=0.66). Scatter plots of individual shedding and lesion frequencies are shown in Figure 2. The duration of HSV-2 shedding episodes and the quantity of HSV-2 on the days that HSV was detected were similar for women using hormonal contraception versus not using hormonal contraception (p=0.61 and p=0.32, respectively) (Table 2).

Open in a separate window

Figure 2.

Scatter plots of individual HSV-2 shedding frequencies (a) and genital lesion frequencies (b) comparing women using and not using hormonal contraception.

Table 1.

Characteristics of study participants using versus not using hormonal contraception.

Hormonal Contraception
(N = 68)No Hormonal Contraception
(N = 189)Median age (range)30 years (20 – 46)33 years (19 – 46)Race, N (%)    White53 (78%)143 (76%)    Non-white14 (21%)45 (24%)    Unknown1 (1%)1 (0%)Median days since HSV-2 infection (range)4 years (1–28)7 years (1–26)Median HSV recurrences per year (range)4.5 (0–14)4 (0–28)Median days swabbed (range)52 days (14 – 127)45 days (6 – 174)

Open in a separate window

Table 2.

HSV-2 shedding and lesions by hormonal contraceptive use

Hormonal Contraception
(N = 68)No Hormonal Contraception
(N = 189)PCR-positive days/total swabs, N(%)675/3691 (18.3%)2036/10715 (19%)Days lesions detected/total days, N(%)320/3677 (8.7%)1272/11447 (11.1%)HSV-2 DNA quantity (log10 copies/mL), median (range)4.7 (2.2 – 9.2)4.7 (2.2 – 9.1)Episode duration (in days), median (range)2 (1, 20)3 (1, 44)

Open in a separate window

Among women who reported using hormonal contraception, HSV-2 shedding and lesion frequency were not found to differ during cycle days 0 to 6 compared to days 7 to 14 after first day of menses and 1 to 14 days prior to menses. HSV-2 DNA was detected on 127 of 809 swabs (15.7%) collected within the 7 days after the first recorded day of menstrual bleeding, and 436 of 2241 swabs (19.5%) collected during the remainder of a 28-day cycle (RR=1.21; 95% CI 0.91–1.59, p=0.19). Lesions were present on 63 of 871 days (7.2%) during this first week, compared to 238 of 2413 days (9.9%) in the remainder of the cycle (p=0.11).

Discussion

This study represents the most comprehensive analysis to date of the association between HSV-2 shedding and lesions and menstrual cycle phase and hormonal contraceptive use. Among women with established HSV-2 infection who are not using hormonal contraception, the follicular phase of the cycle is associated with a higher frequency of HSV-2 shedding compared to the luteal phase. Based on our analysis limited to data within 10 days prior to or after the start of menses, HSV-2 DNA detection is approximately 25% more likely to occur during the follicular phase A similar trend was found in the frequency of genital lesions by phases of the menstrual cycle. Hormonal contraception use was not significantly associated with genital HSV-2 DNA detection or lesions.

The biological mechanisms underlying the difference in HSV-2 shedding frequency observed at different phases of the menstrual cycle are unknown. HSV-2 resides in the sacral ganglia, and during reactivation, travels down the axon to skin and mucosal surfaces.19 A strong immune response within epithelial tissues is required to respond to frequent short bursts of genital shedding in order to attenuate viral replication and prevent the development of genital lesions. Prior studies have demonstrated that markers of innate and adaptive immunity and immune cell populations in the upper and lower genital tract vary during the menstrual cycle, and HSV-2 shedding may be impacted by such variations in immunity.10,12,14 Though studies are inconsistent, the luteal phase of the cycle appears to be associated with a decrease in innate immune factors and an increase in inflammatory cytokines,14,20 which potentially may lead to increased HSV-2 DNA detection in the subsequent week. Interestingly, genital shedding of human immunodeficiency virus (HIV) and cytomegalovirus (CMV) have been found in some studies to vary throughout the menstrual cycle.21,22

In this study, we did not detect a statistically significant association between HSV-2 shedding and lesions and hormonal contraception. The few available studies that have explored an association between HSV-2 shedding and hormonal contraceptive use have had inconsistent findings. An early study of HSV shedding among 27 women collecting daily swabs for viral culture found that contraceptive use and menstrual cycle were not associated with genital HSV-2 shedding.23 However, use of viral culture is about 1/4th as sensitive as PCR, and in this study viral shedding was rare, limiting the power of the study.24 Cherpes et al collected vaginal swabs every 4 months for a year from 330 HSV-2 seropositive women which included both hormonal contraceptive users and nonusers.25 Overall, 9% of swabs had HSV-2 detected. The authors found that users of oral contraceptive pills or depot medroxyprogesterone acetate (DMPA) were approximately twice as likely to shed HSV-2. In the present study, participants collected daily samples providing a more precise measurement of HSV-2 shedding, a greater proportion of swabs were positive for HSV-2, and our analysis excluded women with HSV-2 seroconversion within the past year.

Most studies of hormonal contraception and HSV-2 acquisition have focused on injectable progestin contraceptives such as DMPA. This contraceptive method causes a variety of changes in innate and adaptive immunity and the vaginal microbiome.26 In a mouse model, both DMPA and levonorgestrel increased genital mucosal permeability and susceptibility to HSV-2.27 Among HSV-2 seronegative women, DMPA may increase the risk of HSV-2 acquisition. In a prospective cohort study of 682 HSV-2 negative women in Uganda women who consistently used DMPA had a two-fold higher risk of HSV-2 acquisition.28 A recent study of sex workers in Canada found a four-fold increased risk of HSV-2 acquisition among DMPA users.29 These observations may be related to decreased serum estradiol levels with DMPA and hypoestrogenic effects, which occur less commonly with other methods of hormonal contraception.

This study has several important limitations. First, menstrual cycle phase was estimated by the first day of bleeding reported in participant menstrual diaries. For most women, the shedding session encompassed 1 to 2 menstrual cycles. Cycle phase was not confirmed with serum progesterone testing, and whether study participants were ovulatory or had generally regular menstrual cycles was unknown; some participants may have had abnormal bleeding unrelated to menstruation. Length of cycle phases is highly variable among women, with the follicular (or proliferative) phase ranging from 10 to 23 days, and decreasing as women age.30 The luteal (or secretory) phase is less variable between women and within individuals, but can range from 7 to 19 days. We found a trend but not a significant difference in lesion rate during the follicular phase of the menstrual cycle. As noted in other natural history studies, lesions occurred on approximately half of the days with shedding;8 the lower frequency of lesions results in more limited power to detect differences. We lacked detail regarding specific type of hormonal contraception used, compliance, and specific formulation and dose for oral contraceptive users. Most hormonal contraceptive users in this study likely used the combined oral contraceptive pill on a cyclic regimen, as combined oral contraceptives represent approximately 75% of hormonal contraceptive use in the U.S.31 However, this study encompasses 25 years of data, and trends in contraceptive use as well as available formulations of oral contraceptive pills have changed over time. Future studies need to investigate patterns of HSV-2 shedding and lesions among women using more precisely defined methods of hormonal contraception.

Our findings enable clinicians to reassure women with genital herpes that the use of hormonal contraception is unlikely to increase the frequency of herpes outbreaks or the risk of transmission to a susceptible partner. However, among women not using hormonal contraception, recurrences and shedding may be more frequent during the follicular phase of the cycle (including during menstruation). As recommended in the 2015 Centers for Disease Control and Prevention STD Treatment Guidelines, patients with HSV-2 infection should be encouraged to disclose their HSV status to sexual partners, to use condoms, and to use daily suppressive antiviral therapy to reduce the risk of HSV-2 transmission.32

Acknowledgments

Funding:

National Institute of Child Health and Human Development (NICHD, Grant #K12HD001246), National Institute of Allergy and Infectious Diseases (NIAID, Grant #P01 AI030731).

Footnotes

The authors report no conflicts of interest.

Contributor Information

Elizabeth Micks, Department of Obstetrics and Gynecology University of Washington 1959 NE Pacific St. Box 356460, Seattle, WA 98122, USA.

Hyunju Son, Department of Biostatistics University of Washington Seattle, WA 98122, USA.

Amalia Magaret, Departments of Laboratory Medicine and Biostatistics University of Washington Seattle, WA 98122, USA.

Stacy Selke, Department of Laboratory Medicine University of Washington Seattle, WA 98122, USA.

Christine Johnston, Department of Medicine University of Washington Seattle, WA 98122, USA.

Anna Wald, Departments of Medicine, Laboratory Medicine, and Epidemiology University of Washington Seattle, WA 98122, USA.

References

1. White RG, Freeman EE, Orroth KK, et al. Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect. 2008;84 Suppl 2:ii12–18. [PMC free article] [PubMed] [Google Scholar]

2. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303–1316. [PMC free article] [PubMed] [Google Scholar]

3. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–1153. [PubMed] [Google Scholar]

4. Looker KJ, Magaret AS, May MT, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017;5(3):e300–e309. [PMC free article] [PubMed] [Google Scholar]

5. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999;341(19):1432–1438. [PubMed] [Google Scholar]

6. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116(3):197–202. [PubMed] [Google Scholar]

7. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342(12):844–850. [PubMed] [Google Scholar]

8. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441–1449. [PMC free article] [PubMed] [Google Scholar]

9. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011;203(2):180–187. [PMC free article] [PubMed] [Google Scholar]

10. Birse K, Arnold KB, Novak RM, et al. Molecular Signatures of Immune Activation and Epithelial Barrier Remodeling Are Enhanced during the Luteal Phase of the Menstrual Cycle: Implications for HIV Susceptibility. J Virol. 2015;89(17):8793–8805. [PMC free article] [PubMed] [Google Scholar]

11. Thurman AR, Chandra N, Yousefieh N, et al. Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women. AIDS Res Hum Retroviruses. 2016;32(6):547–560. [PMC free article] [PubMed] [Google Scholar]

12. Wira CR, Rodriguez-Garcia M, Patel MV. The role of sex hormones in immune protection of the female reproductive tract. Nat Rev Immunol. 2015;15(4):217–230. [PMC free article] [PubMed] [Google Scholar]

13. Kyongo JK, Jespers V, Goovaerts O, et al. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One. 2012;7(8):e43951. [PMC free article] [PubMed] [Google Scholar]

14. Macneill C, de Guzman G, Sousa GE, et al. Cyclic changes in the level of the innate immune molecule, surfactant protein-a, and cytokines in vaginal fluid. Am J Reprod Immunol. 2012;68(3):244–250. [PMC free article] [PubMed] [Google Scholar]

15. Guinan ME, MacCalman J, Kern ER, Overall JC, Jr., Spruance SL. The course of untreated recurrent genital herpes simplex infection in 27 women. N Engl J Med. 1981;304(13):759–763. [PubMed] [Google Scholar]

16. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996;124(1 Pt 1):8–15. [PubMed] [Google Scholar]

17. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26(4):662–667. [PMC free article] [PubMed] [Google Scholar]

18. Jerome KR, Huang ML, Wald A, Selke S, Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol. 2002;40(7):2609–2611. [PMC free article] [PubMed] [Google Scholar]

19. Johnston C, Corey L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev. 2016;29(1):149–161. [PMC free article] [PubMed] [Google Scholar]

20. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21(4):467–476. [PubMed] [Google Scholar]

21. Curlin ME, Leelawiwat W, Dunne EF, et al. Cyclic changes in HIV shedding from the female genital tract during the menstrual cycle. J Infect Dis. 2013;207(10):1616–1620. [PubMed] [Google Scholar]

22. Mostad SB, Kreiss JK, Ryncarz A, et al. Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. Am J Obstet Gynecol. 2000;183(4):948–955. [PubMed] [Google Scholar]

23. Brock BV, Selke S, Benedetti J, Douglas JM, Jr., Corey L. Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. JAMA. 1990;263(3):418–420. [PubMed] [Google Scholar]

24. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188(9):1345–1351. [PubMed] [Google Scholar]

25. Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis. 2005;40(10):1422–1428. [PubMed] [Google Scholar]

26. Roxby AC, Fredricks DN, Odem-Davis K, et al. Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. J Acquir Immune Defic Syndr. 2016;71(4):359–366. [PMC free article] [PubMed] [Google Scholar]

27. Quispe Calla NE, Vicetti Miguel RD, Boyaka PN, et al. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. Mucosal Immunol. 2016;9(6):1571–1583. [PMC free article] [PubMed] [Google Scholar]

28. Grabowski MK, Gray RH, Makumbi F, et al. Use of injectable hormonal contraception and women’s risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda. Lancet Glob Health. 2015;3(8):e478–e486. [PMC free article] [PubMed] [Google Scholar]

29. Socias ME, Duff P, Shoveller J, et al. Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada. Sex Transm Infect. 2017;93(4):284–289. [PMC free article] [PubMed] [Google Scholar]

30. Vitzthum VJ. The ecology and evolutionary endocrinology of reproduction in the human female. Am J Phys Anthropol. 2009;140 Suppl 49:95–136. [PubMed] [Google Scholar]

31. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: Trends and characteristics between 2008, 2012 and 2014

Why do I get herpes outbreaks during my period?

How can I control herpes near my period?

How can I stop a monthly herpes outbreak?

Can menstrual blood carry herpes?